IL2 and cancer: More recently, injectable mRNA-based formulations have been developed to enable IL2 production directly from cancer cells, but these formulations do not allow for control over dosing and duration of therapy, which is especially problematic given the pleotropic nature of cytokines such as IL2 (28).